Exicure Achieves Milestone in Collaboration with GPCR Therapeutics
I'm PortAI, I can summarize articles.
Exicure Inc. has reached a milestone in its collaboration with GPCR Therapeutics Inc. by completing a Phase 2 clinical trial for its stem cell mobilizer. This achievement triggers a $1 million milestone payment to GPCR and activates a sublicensing income-sharing agreement. The collaboration centers on Burixafor (GPC-100), a small molecule CXCR4 inhibitor.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments